Novavax, Inc. (NASDAQ:NVAX) Reports Remarkable Results On Its Flu Vaccine

0
542

The Phase 1/2 clinical trial of NanoFlu recombinant influenza vaccine, which was tried on older adults, was positive according to Novavax, Inc. (NASDAQ:NVAX). Results of the trial indicate that the vaccine was well tolerated over the three-week trial period compared to the H3N2 strain. The latter is reportedly a common public health challenge and has been linked to about 75% flu-related hospitalizations. The findings of the trial also revealed a significant immune response from HAI against the H3N2 strains.

This is a significant milestone for the NanoFlu vaccine and Novavax says that it is set to begin a Phase 2 trial in the third quarter of 2018. The vaccine uses HA amino acid protein sequences, which are more or less a replica of wild-type circulating virus HA sequences.

Novavax is an appealing player in the healthcare space

It is estimated that close to 85 percent of seniors experience flu-related complications from the age of 65years. However, Novavax has taken up the responsibility of dealing with the situation. The company has maintained a good focus on Biotechnology and it is currently trading with a market capitalization of $749.49 Million.

The Gaithersburg based company recorded a 52-week high of $2.60 and in the past month, it has made a move of +9.39%. This translates into Strong relative transaction volume.

Let’s explore NanoFlu

The vaccine is generated by Novavax in its SF9 insect cell-baculovirus system. It includes Novavax’ patented saponin-based Matrix-M adjuvant, which has also proved to be competent. Its role is to stimulate the admission of antigen-presenting cells into the injection location.

Meanwhile, Novavax has vowed to tighten its commitment in the delivery of novel products, which are expected to thwart a broad range of infectious diseases. The vows come at a time when the need for innovation and improvement of global health is increasing. The company’s pipeline of products targets a variety of infectious diseases. It is also putting in place a preclinical program for regrouping of the respiratory vaccine candidate.

LEAVE A REPLY

Please enter your comment!
Please enter your name here